Danaher (NYSE:DHR) Price Target Cut to $260.00

Danaher (NYSE:DHR – Get Rating) had its price target lowered by Barclays from $270.00 to $260.00 in a report released on Wednesday, The Fly reports. Barclays‘s price objective would indicate a potential upside of 12.35% from the company’s current price.

Several other research firms have also recently weighed in on DHR. Robert W. Baird reduced their price objective on Danaher from $321.00 to $309.00 in a research report on Wednesday, January 25th. Bank of America cut Danaher from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $310.00 to $250.00 in a research report on Wednesday. Cowen reduced their price target on Danaher from $340.00 to $320.00 and set an “outperform” rating for the company in a research report on Wednesday, January 25th. StockNews.com started coverage on Danaher in a research report on Thursday, March 16th. They set a “buy” rating for the company. Finally, Wells Fargo & Company raised Danaher from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $275.00 to $285.00 in a research report on Tuesday, April 18th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $293.71.

Get Danaher alerts:

Danaher Stock Down 0.5 %

Shares of Danaher stock opened at $231.42 on Wednesday. Danaher has a 1 year low of $227.00 and a 1 year high of $303.82. The business has a 50-day moving average of $247.95 and a two-hundred day moving average of $257.21. The company has a market capitalization of $168.73 billion, a P/E ratio of 23.98, a price-to-earnings-growth ratio of 1.90 and a beta of 0.80. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.89 and a quick ratio of 1.52.

Danaher (NYSE:DHR – Get Rating) last posted its quarterly earnings data on Tuesday, April 25th. The conglomerate reported $2.36 earnings per share for the quarter, topping the consensus estimate of $2.26 by $0.10. The company had revenue of $7.17 billion during the quarter, compared to analysts’ expectations of $7.06 billion. Danaher had a return on equity of 17.02% and a net margin of 22.40%. Danaher’s revenue for the quarter was down 6.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.76 earnings per share. As a group, equities analysts predict that Danaher will post 10.17 EPS for the current year.

Hedge Funds Weigh In On Danaher

Large investors have recently made changes to their positions in the company. Equitable Holdings Inc. increased its stake in shares of Danaher by 12.4% during the third quarter. Equitable Holdings Inc. now owns 3,286 shares of the conglomerate’s stock worth $849,000 after purchasing an additional 362 shares during the period. AE Wealth Management LLC increased its stake in shares of Danaher by 1.6% during the fourth quarter. AE Wealth Management LLC now owns 29,903 shares of the conglomerate’s stock worth $7,937,000 after purchasing an additional 485 shares during the period. Procyon Advisors LLC increased its stake in shares of Danaher by 42.8% during the fourth quarter. Procyon Advisors LLC now owns 2,985 shares of the conglomerate’s stock worth $792,000 after purchasing an additional 895 shares during the period. Mount Yale Investment Advisors LLC increased its stake in Danaher by 12.7% during the 3rd quarter. Mount Yale Investment Advisors LLC now owns 4,589 shares of the conglomerate’s stock worth $1,185,000 after acquiring an additional 518 shares during the period. Finally, CWM LLC increased its stake in Danaher by 23.1% during the 3rd quarter. CWM LLC now owns 17,782 shares of the conglomerate’s stock worth $4,593,000 after acquiring an additional 3,342 shares during the period. Institutional investors own 77.26% of the company’s stock.

Danaher Company Profile

(Get Rating)

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services.

See Also

• Get a free copy of the StockNews.com research report on Danaher (DHR)
• 10 E-commerce Stocks to Consider for Long-Term Buys
• Joby Aviation Extends Deal With Air Force, Analysts Maintain Hold
• Meta’s Earnings; Time To Buckle Up
• Why Invest in High-Yield Dividend Stocks?
• Dividend Prince Automatic Data Processing Hits Bottom

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.